Ernst Moritz Arndt University, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, 3 Felix Hausdorff Street, Greifswald, 17489, Germany.
Ernst Moritz Arndt University, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, 3 Felix Hausdorff Street, Greifswald, 17489, Germany.
Int J Pharm. 2017 Nov 25;533(1):298-314. doi: 10.1016/j.ijpharm.2017.08.126. Epub 2017 Sep 21.
Parkinson's disease (PD) is a progressive neurodegenerative disease that presents with visible motor symptoms, but that is accompanied by several additional symptoms, including gastrointestinal symptoms that may affect pharmacokinetics of oral medications. A detailed understanding of the nature of PD-specific gastrointestinal parameters and of how they may affect drug release of orally administered dosage forms seems to be essential information for developing better oral PD medications. The availability of bio-predictive drug release models simulating PD-specific gastrointestinal parameters would also be beneficial for this purpose. The focus of the present literature review was to determine PD-specific gastrointestinal parameters that will allow for the development of a test methodology simulating the gastrointestinal passage of orally administered medications in PD patients. Whereas for some gastrointestinal segments there is quite a reasonable set of data available on fluid volumes, motility and passage times, for others there is still a big lack in information that would be required for simulating a detailed gastrointestinal passage in a PD patient. The latter is particularly true for potential disease-related changes in gastrointestinal fluid composition. However, with the availability of novel non-invasive diagnostic options there is a chance of obtaining more information in the near future.
帕金森病（PD）是一种进行性神经退行性疾病，表现为明显的运动症状，但伴有其他几种症状，包括胃肠道症状，这些症状可能会影响口服药物的药代动力学。详细了解 PD 特异性胃肠道参数的性质以及它们如何影响口服剂型的药物释放，似乎是开发更好的口服 PD 药物的重要信息。具有模拟 PD 特异性胃肠道参数的生物预测药物释放模型的可用性也将对此有所帮助。本文献综述的重点是确定 PD 特异性胃肠道参数，这些参数将允许开发一种测试方法，模拟 PD 患者口服药物的胃肠道通过。虽然对于一些胃肠道段，有关液体量、运动和通过时间的数据相当合理，但对于其他胃肠道段，仍然缺乏模拟 PD 患者详细胃肠道通过所需的信息。对于胃肠道液体成分的潜在疾病相关变化尤其如此。然而，随着新型非侵入性诊断选择的出现，在不久的将来有机会获得更多信息。
